Detalhe da pesquisa
1.
Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
Proc Natl Acad Sci U S A
; 119(38): e2202727119, 2022 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099300
2.
Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.
Eur Heart J
; 44(46): 4878-4889, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36806405
3.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526149
4.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Breast Cancer Res Treat
; 195(3): 341-351, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986801
5.
Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
Mod Pathol
; 35(3): 396-402, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593966
6.
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Cochrane Database Syst Rev
; 4: CD011395, 2021 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33886122
7.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat
; 183(1): 227-237, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32613539
8.
Male breast cancer: a disease distinct from female breast cancer.
Breast Cancer Res Treat
; 173(1): 37-48, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30267249
9.
Emerging Novel Therapeutics in Triple-Negative Breast Cancer.
Adv Exp Med Biol
; 1152: 377-399, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456195
10.
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 111-120, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29744674
11.
First international TNBC conference meeting report.
Breast Cancer Res Treat
; 169(3): 407-412, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29417299
12.
The Androgen Receptor: Is It a Promising Target?
Ann Surg Oncol
; 24(10): 2876-2880, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28766215
13.
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.
NPJ Breast Cancer
; 10(1): 8, 2024 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242892
14.
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(7): 1240-1247, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38236575
15.
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.
Breast Cancer Res Treat
; 139(2): 497-506, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645006
16.
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
medRxiv
; 2023 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945501
17.
Androgen receptor-positive, triple-negative breast cancer.
Cancer
; 123(10): 1686-1688, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28406524
18.
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 131(1): 111-6, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21898114
19.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol
; 40(5): 449-458, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995105
20.
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Cancer
; 117(18): 4125-31, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21387266